CAJ | 학술논문

目的：观察原发性乳房外Paget病中HER-2/neu基因扩增及HER-2蛋白的表达，探讨其在乳房外Paget病中的意义。方法：收集2007年1月-2011年9月原发性乳房外Paget病手术切除标本20份，应用显色原位杂交和免疫组织化学的方法，分别检测患者皮损组织石蜡包埋标本中HER-2/neu基因扩增和HER-2蛋白表达情况。结果：所有20例患者分为3组：免疫组织化学检测HER-2蛋白高表达组、低表达组和阴性表达组分别为8例、6例和6例，HER-2蛋白阳性表达率为70.0％。显色原位杂交检测高扩增组、低扩增组和无扩增组分别为7例、2例和11例，HER-2基因的扩增率为45.0％。采用Spearman秩相关进行分析，两种检测方法的结果具有正相关性(P＜0.05)。结论：在原发性乳房外Paget病中存在HER-2/neu基因扩增和HER-2蛋白的表达，两者之间存在正相关性。干扰HER-2蛋白的表达可能为临床治疗原发性乳房外Paget病提供一种新的策略。
목적：관찰원발성유방외Paget병중HER-2/neu기인확증급HER-2단백적표체，탐토기재유방외Paget병중적의의。방법：수집2007년1월-2011년9월원발성유방외Paget병수술절제표본20빈，응용현색원위잡교화면역조직화학적방법，분별검측환자피손조직석사포매표본중HER-2/neu기인확증화HER-2단백표체정황。결과：소유20례환자분위3조：면역조직화학검측HER-2단백고표체조、저표체조화음성표체조분별위8례、6례화6례，HER-2단백양성표체솔위70.0％。현색원위잡교검측고확증조、저확증조화무확증조분별위7례、2례화11례，HER-2기인적확증솔위45.0％。채용Spearman질상관진행분석，량충검측방법적결과구유정상관성(P＜0.05)。결론：재원발성유방외Paget병중존재HER-2/neu기인확증화HER-2단백적표체，량자지간존재정상관성。간우HER-2단백적표체가능위림상치료원발성유방외Paget병제공일충신적책략。
Objective: To observe the HER-2 protein expression and HER-2/neu gene amplification in primary extramam-mary Paget’s disease(EMPD) and to investigate HER-2’s significance in Paget’s disease. Methods: A total of 20 cases of EMPD were enrolled into the study from Jan. 2007 to Sep. 2011. Immunohistochemistry(IHC) and chromogenic in situ hy-bridization(CISH) methods were used to detect the HER-2 protein expression and HER-2/neu gene amplification in paraffin-embedded surgical specimens respectively. Results:The results of HER-2 protein were divided into three groups:high expres-sion(8/20), low expression(6/20) and negative expression(6/20) by IHC. The positive expression is up to 70%. The results of HER-2/neu gene were also divided into three groups: high amplification(7/20), low amplification(2/20) and negative amplifi-cation(11/20) by CISH. The positive amplification reaches 45%. The correlation of HER-2 protein measured by IHC and HER-2/neu gene detected by CISH with Spearman rank correlation analysis , the result showed that the correlation of two methods is positive(P<0.05). Conclusions: HER-2 protein expression and HER-2/neu gene amplification are existed in most cases of EMPD. The interference of HER-2 protein expression may provide a new strategy for the clinical management of EMPD.